HDM

Welcome Curtis Cole, MD, to HDM's Board of Directors: A Mission-Driven Leader Aligned with HDM's Vision

Retrieved on: 
星期三, 十一月 22, 2023
The arts, Weill Cornell Medicine, Bowdoin College, Cornell University, Columbia, Patient, HDM, Bachelor of Arts, AIDS, Health, Columbia University, AI, Education, Management, Nursing, Cole, MD

NEW YORK, Nov. 22, 2023 /PRNewswire-PRWeb/ -- Health Data Movers (HDM), a leading healthcare technology services firm, welcomes Curtis Cole, MD, to the company's Board of Directors.

Key Points: 
  • NEW YORK, Nov. 22, 2023 /PRNewswire-PRWeb/ -- Health Data Movers (HDM), a leading healthcare technology services firm, welcomes Curtis Cole, MD, to the company's Board of Directors.
  • Cole graduated from Bowdoin College in 1986 with a Bachelor of Arts and completed pre-med studies at Columbia University 1987-89.
  • Post-graduation from Cornell Medicine in 1994, he completed his residency at New York Presbyterian and Cornell Medical Center.
  • HDM's values are also essential to building the trust healthcare providers need to stay true to their mission while pursuing complicated new technologies."

ProLabs to Showcase OpenZR+ and Fiber Connectivity Solutions at SCTE Cable-Tec Expo 2023

Retrieved on: 
星期一, 十月 16, 2023
DWDM, MPO, ARIA, LC, HDM, MSA, Temperature, QSFP, Colorado Convention Center, MDX, Microducts, SCTE, Bidirectional text, Internet service provider, Video game, Printed circuit board

ProLabs offers service provider networks solutions to the challenges of reducing bottlenecks throughout the network—from the core to the access network.

Key Points: 
  • ProLabs offers service provider networks solutions to the challenges of reducing bottlenecks throughout the network—from the core to the access network.
  • At Cable-Tec Expo 2023, ProLabs will showcase its latest advancements to support this evolution to faster, further fiber communications:
    OpenZR+—ProLabs has a complete complement of OpenZR+ coherent 400G pluggable transceivers that increase capacity over long-haul and metro networks directly from an Ethernet host.
  • Fiber Connectivity—ProLabs' line of ARIA fiber connectivity solutions features products that support greater densities for growing fiber connections in the data center as well as the outside plant.
  • Visit ProLabs in booth 1207 at Cable-Tec Expo 2023 to see the latest innovations.

Foresee Pharmaceuticals Presents Data From its Aderamastat Program at The European Respiratory Society (ERS) International Congress 2023

Retrieved on: 
星期二, 九月 12, 2023
European Respiratory Society, Human, Asthma, International, HDM, IOS, Lung, ERS, Foresight, Patient, SNP, LAR, AX, Second International Congress on Education of the Deaf, FEV1, Pharmaceutical industry, R5

TAIPEI, Sept. 12, 2023 /PRNewswire/ -- Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") announced today that the company presented the positive primary outcomes of its aderamastat (FP-025) Phase 2 proof-of-concept allergic asthma study at the European Respiratory Society (ERS) International Congress 2023 taking place in Milan, Italy from September 9-13, 2023.

Key Points: 
  • Late-breaking oral presentation on the positive primary outcomes of aderamastat, a first-in-class, oral MMP-12 inhibitor in a Phase 2 Phase 2 proof-of-concept allergic asthma study, supporting potential novel anti-inflammatory mechanism for respiratory diseases.
  • TAIPEI, Sept. 12, 2023 /PRNewswire/ -- Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") announced today that the company presented the positive primary outcomes of its aderamastat (FP-025) Phase 2 proof-of-concept allergic asthma study at the European Respiratory Society (ERS) International Congress 2023 taking place in Milan, Italy from September 9-13, 2023.
  • It was a real pleasure to share this promising data with such a remarkable group of scientists and clinicians in the field of respiratory diseases.
  • "This Phase 2 study demonstrates that the inhibition of MMP-12 in humans is in line with the MMP-12 single-nucleotide polymorphism (SNP) data, human expression data, and animal pharmacology models.

Foresee Pharmaceuticals Presents Data From its Aderamastat Program at The European Respiratory Society (ERS) International Congress 2023

Retrieved on: 
星期二, 九月 12, 2023
European Respiratory Society, Human, Asthma, International, HDM, IOS, Lung, ERS, Foresight, Patient, SNP, LAR, AX, Second International Congress on Education of the Deaf, FEV1, Pharmaceutical industry, R5

TAIPEI, Sept. 11, 2023 /PRNewswire/ -- Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") announced today that the company presented the positive primary outcomes of its aderamastat (FP-025) Phase 2 proof-of-concept allergic asthma study at the European Respiratory Society (ERS) International Congress 2023 taking place in Milan, Italy from September 9-13, 2023.

Key Points: 
  • Late-breaking oral presentation on the positive primary outcomes of aderamastat, a first-in-class, oral MMP-12 inhibitor in a Phase 2 Phase 2 proof-of-concept allergic asthma study, supporting potential novel anti-inflammatory mechanism for respiratory diseases.
  • TAIPEI, Sept. 11, 2023 /PRNewswire/ -- Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") announced today that the company presented the positive primary outcomes of its aderamastat (FP-025) Phase 2 proof-of-concept allergic asthma study at the European Respiratory Society (ERS) International Congress 2023 taking place in Milan, Italy from September 9-13, 2023.
  • It was a real pleasure to share this promising data with such a remarkable group of scientists and clinicians in the field of respiratory diseases.
  • "This Phase 2 study demonstrates that the inhibition of MMP-12 in humans is in line with the MMP-12 single-nucleotide polymorphism (SNP) data, human expression data, and animal pharmacology models.

Six-month interim report (Q2) 2023

Retrieved on: 
星期四, 八月 24, 2023
Government, Plasma protein binding, Growth, Ageing, Allergy, EBIT, HDM, Peanut allergy, ALK, Pharmaceutical industry

Top-line results from the TT-06 paediatric Phase 3 trial with the tree tablet are still expected in Q4 2023.

Key Points: 
  • Top-line results from the TT-06 paediatric Phase 3 trial with the tree tablet are still expected in Q4 2023.
  • First readouts from the Phase 1 trial of tablet treatment for peanut allergy are still expected end-2023.
  • 2023 revenue outlook is narrowed; earnings outlook remains unchanged
    The full-year revenue outlook has been narrowed to mainly reflect the year-to-date progress and intermittent supply shortages affecting Jext®.
  • Tablets sales and SCIT/SLIT-drops sales are still expected to grow by double digits respectively in the second half of the year.

Altamira Therapeutics Announces Publication of Positive Results from Clinical Trial with Bentrio in House Dust Mite Allergy in Leading Peer Reviewed Journal

Retrieved on: 
星期一, 七月 17, 2023
Therapy, HDM, Clinical trial, Altamira, Allergic rhinitis, History, ANCOVA, PAR, Patient, Pharmaceutical industry, Medical imaging

Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced the publication of the detailed results from its clinical trial with Bentrio® nasal spray in house dust mite (“HDM”) allergic rhinitis.

Key Points: 
  • Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced the publication of the detailed results from its clinical trial with Bentrio® nasal spray in house dust mite (“HDM”) allergic rhinitis.
  • The peer-reviewed article was published in Clinical and Translational Allergy, one of the leading journals in the field of allergology.
  • The primary endpoint was the change in the Total Nasal Symptom Score (TNSS; determined in 20-minute intervals) from baseline.
  • “Also, in both studies Bentrio exhibited a lasting protective effect for several hours, reflecting its long nasal residence time.

Annual Congress 2023 of the European Academy of Allergy and Clinical Immunology: Groundbreaking Study Validates Allergen Exposure Chamber for Assessing Clinical Outcomes of HDM AIT in Allergic Rhinoconjunctivitis Patients'

Retrieved on: 
星期日, 六月 11, 2023
AIT, HDM, Huntington Medical Research Institutes, Wrocław Medical University, VAS, Visual analogue scale, Conjunctivitis, Patient, AEC, Immunoglobulin E, Safety, Medical imaging

The study focused on evaluating the efficacy and safety of AEC-derived clinical outcomes of subcutaneous HDM AIT, a treatment designed to alleviate symptoms triggered by HDM allergies.

Key Points: 
  • The study focused on evaluating the efficacy and safety of AEC-derived clinical outcomes of subcutaneous HDM AIT, a treatment designed to alleviate symptoms triggered by HDM allergies.
  • Fifty patients with HDM-triggered allergic rhinoconjunctivitis were included in the study, with HDM allergy confirmed through various diagnostic tests such as skin prick tests, serum-specific IgE, and basophil activation tests.
  • During the study, patients were assessed in the allergen exposure chamber before commencing AIT and after 12 months of treatment.
  • The chamber provided a controlled environment, allowing patients to be exposed to HDM allergen under stable and well-regulated conditions.

Large Phase 3 clinical trial successfully meets primary endpoint, confirming the potential of ALK’s house dust mite tablet in young children

Retrieved on: 
星期四, 六月 8, 2023
Clinical trial, Allergic rhinitis, Patient, HDM, ALK, Medical imaging

The trial achieved its primary endpoint with an improvement of 22% in the total combined rhinitis score (TCRS) compared to placebo treated patients.

Key Points: 
  • The trial achieved its primary endpoint with an improvement of 22% in the total combined rhinitis score (TCRS) compared to placebo treated patients.
  • All key secondary endpoints were also met, further confirming the efficacy of the HDM tablet.
  • The trial was well conducted with more than 95% of patients maintaining treatment throughout the trial.
  • Subject to approval, the HDM tablet could be available for young children in Europe and North America in 2024/25.

MEDITECH featured in Four-Part Docuseries

Retrieved on: 
星期二, 六月 6, 2023
General Health, Health Technology, Health, Culture, HDM, Vision, Journey, Multimedia, Journey Beyond Tomorrow, Patient, EHR, Tenacity, MEDITECH, Television, Management, KLAS

Following MEDITECH’s recent Best in KLAS recognition, Health Data Management (HDM) invited the EHR vendor to participate in a four-part docuseries highlighting their vision for the future of healthcare.

Key Points: 
  • Following MEDITECH’s recent Best in KLAS recognition, Health Data Management (HDM) invited the EHR vendor to participate in a four-part docuseries highlighting their vision for the future of healthcare.
  • View the full release here: https://www.businesswire.com/news/home/20230606005328/en/
    The MEDITECH’s Might docuseries is part of HDM’s The Journey Beyond: Exploring uncharted territories - examining how organizational struggles and victories have shaped the highest performing institutions in the world.
  • Leaders including MEDITECH President & CEO Michelle O’Connor and Executive Vice President & COO Helen Waters share how, after more than 50 years in business, the company’s dedication to continuous innovation has positioned them for future success.
  • “There is something special happening here at MEDITECH,” he said.

Privoro and Samsung partner to provide trusted control over smartphone radios and sensors

Retrieved on: 
星期一, 五月 8, 2023
Federation, Partnership, Samsung Galaxy S22, Samsung Electronics, Agility, HDM, Electronics, Samsung, Research, Organization, Samsung Knox, Risk, Hardware, MDM, Environment, Mobile phone

CHANDLER, Ariz., May 8, 2023 /PRNewswire/ -- Privoro, a next-generation mobile security hardware company, today announced a new partnership with Samsung Electronics to provide a first-of-its-kind security capability for mobile devices. The new capability provides a critical shield against the invisible threat posed by modern cyberweapons via high-assurance control over the radios, sensors and other peripherals within a commercial mobile device.

Key Points: 
  • The new capability provides a critical shield against the invisible threat posed by modern cyberweapons via high-assurance control over the radios, sensors and other peripherals within a commercial mobile device.
  • "Mobile devices have become the primary computing devices on the planet, with the resultant focus from threat actors," said Mike Fong, founder and CEO of Privoro.
  • Starting with Galaxy S22, a hardware-to-hardware integration between Privoro's SafeCase security device and Galaxy's Hardware Device Manager (HDM) enables SafeCase to independently control the phone's hardware peripherals.
  • "The security benefits provided by Samsung Knox are greatly strengthened through the off-device hardware isolation provided by Privoro's SafeCase."